DEFERRED REVENUE (Details Narrative) - USD ($) |
9 Months Ended | |
---|---|---|
Dec. 31, 2022 |
Mar. 31, 2022 |
|
Defined Benefit Plan Disclosure [Line Items] | ||
Deferred revenues | $ 35,556 | $ 45,559 |
Deferred revenues current component | 13,333 | 13,333 |
Deferred revenues long-term component | 22,223 | $ 32,226 |
TAGI Pharma [Member] | ||
Defined Benefit Plan Disclosure [Line Items] | ||
Unamortized amount | $ 200,000 | |
Licensing agreement beginning | Sep. 30, 2010 | |
Licensing agreement ending | Aug. 31, 2025 |
X | ||||||||||
- Definition Latest date the outstanding debt instruments are required to be repaid, in YYYY-MM-DD format. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Earliest date the outstanding debt instruments are required to be repaid, in YYYY-MM-DD format. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Amount, after accumulated amortization, of debt premium. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
X | ||||||||||
- Definition Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
X | ||||||||||
- Definition Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
X | ||||||||||
- Details
|